2020 - Updates & Insights Blog
-
An Introduction to Proteogenomics Part 2: Wielding the Proteomic ToolsIn the second guest post from the Office of Cancer Clinical Proteomics Research, our colleagues describe how proteogenomic research is done and some of the findings made so far about tumor subtypes, immune microenvironment, and other aspects of tumor biology. Many of the new insights were enabled by combining genomic and proteomic data.
-
Brain Tumors Hack the Neuronal Microenvironment in Multiple Ways to Drive Tumor GrowthA glioblastoma genetic screen done in mice shows how very different pathways can be altered by different variants of the same key gene—in this case PIK3CA. Tumor cells may even act on neighboring, wild type cells to promote tumorigenesis. The work was led by Drs. Benjamin Deneen, Kenneth Scott, and Gordon Mills, researchers from NCI’s Cancer Target Discovery and Development (CTD^2) Network.
-
An Introduction to Proteogenomics: Appreciating the Complexity of the Central DogmaMany layers of regulation affect the flow of information from DNA to RNA to protein. In a guest post from the Office of Cancer Clinical Proteomics Research, our colleagues describe the importance of incorporating proteomics to better understand—and potentially treat—the complexities of cancer.
-
Visualizing Single-Cell RNA-Seq Data with t-SNE: Researcher Interview with Dmitry Kobak and Philipp BerensTo visualize and interpret single-cell RNA-seq data, researchers must select from endless combinations of computational methods and parameters. Dr. Dmitry Kobak and Dr. Philipp Berens discuss the pros and cons of one popular method in “The art of using t-SNE for single-cell transcriptomics.”
-
Contributing to Precision Oncology by Expanding Basic Research Capacities Using Next-Generation Cancer ModelsDr. Julyann Pérez-Mayoral, a new program manager for the Human Cancer Models Initiative (HCMI) shares her background and aspirations for her new role at the Office of Cancer Genomics.
-
Bridging the Gap: CTD² Network Research Findings Undergoing Testing in Clinical TrialsExamples of how CTD² Network research is informing the development of small molecule inhibitors, immunological agents, and other therapies and leading to clinical trials for various cancers.
-
Next-Generation Cancer Models Available as a Community ResourceHCMI is an international consortium generating patient-derived next-gen cancer models and case-associated data as a community resource. Get the latest updates on the models available through the Searchable Catalog and case-associated data at the Genomic Data Commons.
-
Immunoprofiler Consortium at the University of California, San Francisco (UCSF)The UCSF Immunoprofiler Consortium aims to understand the nature of immune responses across various cancers and identify biomarkers to discover targets for new therapeutic interventions.
-
Analysis of Ugandan Cervical Carcinomas Identifies Human Papillomavirus (HPV) Clade-specific Epigenome and Transcriptome LandscapesA study conducted in Ugandan cervical cancer patients as a part of HIV+ Tumor Molecular Characterization Project helps define the molecular landscape of the disease and describes different human papillomavirus (HPV) clades, influence of HIV status and genetic background in cervical cancer.
-
Continuing Our Work in the Time of Two PandemicsCCG Director Lou Staudt reflects on two pandemics—COVID-19 and racial injustice—and resolves to use the scientific method to address health care disparities.